In conclusion, patients with initially unresectable HCC who received combination therapy of a TKI with an anti–PD-1 antibody had a longer TTR after hepatectomy if they had achieved pCR after systemic therapy. The gene discussed is RPL17; the disease is hepatocellular carcinoma.